Aug 26, 2011

Baxter to Acquire Privately Held Baxa Corporation for $380 Million

Baxter to Acquire Privately Held Baxa Corporation

Acquisition Complements Baxter’s Broad Nutrition and Drug Delivery Portfolio

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today that it has entered into a definitive agreement to acquire Baxa Corporation, a privately held company based in Englewood, Colo., with additional operations in Florida and the United Kingdom. Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery. The addition of Baxa’s product lines will complement Baxter’s portfolio of nutrition products and drug delivery systems and supports patient safety.

With these new offerings, Baxter will be able to provide a comprehensive solution to fulfill the majority of patients’ nutritional requirements and increase efficiency in the pharmacy,” said Robert M. Davis, president of Baxter’s Medical Products business. “Bringing this expertise together with Baxter’s commercial capabilities and global reach will enable us to continue to meet our customers' evolving needs and extend our position in IV nutrition and fluid delivery.”

The transaction includes a total upfront cash consideration of $380 million and is expected to close following satisfaction of customary closing conditions and the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Annual sales for Baxa were approximately $150 million in 2010, and Baxter expects the future top-line growth of this business to be accretive to the company’s future sales growth. In addition, Baxter expects this transaction to be neutral to full-year 2012 earnings excluding dilution of approximately $0.03 to $0.05 per diluted share related to acquisition accounting and transaction-related expenses, and increasingly accretive thereafter.

Nutrition is recognized as an important element of patients’ therapy, and both Baxter and Baxa have sought to advance the delivery of IV nutrition through innovative technologies such as Baxter’s multi-chamber, premixed containers and Baxa’s automated compounding systems.

Baxter’s multi-chamber containers are prefilled and provide many of the essential ingredients of balanced nutrition for a wide range of patients. Baxa’s pharmacy integration and automation technology allow hospital pharmacists to customize treatment for specific patient populations when needed.

In response to the growing need to eliminate sources of potential error, both premixed medications and pharmacy automation help to reduce medication errors and improve operational effectiveness. Among Baxa’s numerous offerings are the ExactaMix® Compounder, devices that automate multi-ingredient nutritional solution compounding and the DoseEdge® Pharmacy Workflow Manager, an integrated system for managing IV and oral dose preparation activities.

Baxa products play a trusted role in the preparation of hundreds of thousands of safe doses of medication every day. “With this agreement, Baxa will be able to play a greater role in delivering safe medication practices,” said Greg Baldwin, Baxa chairman and chief executive officer. “We are very pleased to find a partner that shares our commitment and sees the potential in our products, technology and people.”

About Baxter’s Medical Products Business

Baxter’s Medical Products business develops and provides products used in the delivery of fluids and drugs to patients. These include IV solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, inhalation anesthetics and products and services for people with end-stage kidney disease. At the forefront of IV nutrition, Baxter’s ongoing advancements include multi-chamber containers, lipids, amino acids, vitamins and admixing technology.

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning a definitive agreement entered into between the company and Baxa, including expectations with respect to the closing of the transaction and its financial impact on the company. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety issues; failure to obtain the necessary consents or to satisfy other closing conditions; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.

 

Contacts

Baxter International Inc.
Media Contacts
Christy Noland, (847) 948-4380
Deborah Spak, (847) 948-2349
or
Investor Contacts
Mary Kay Ladone, (847) 948-3371
Clare Trachtman, (847) 948-3085

 

Baxter Press Release

Market Buzz

Apr 22, 2019 Visante healthcare consulting firm announces Judi Jacobi, PharmD, to join consul...
Apr 17, 2019 As an aging population demands more efficient pharmacy solutions, the founder of...
Apr 17, 2019 Adam Wallace Named Chief Technology Officer at Transaction Data Systems (TDS)
Apr 15, 2019 PharmaLink to Exhibit at 2019 Asembia Specialty Pharmacy Summit
Apr 04, 2019 Transaction Data Systems (TDS) Announces Acquisition of Pharm Assess, Inc.
Apr 01, 2019 Chad Collins Named President of Akro-Mils and Jamco Products
Mar 22, 2019 Tutela Welcomes Octapharma Plasma
Mar 18, 2019 Verity Solutions Recognized as Category Leader for 340B Management Systems in 20...
Mar 07, 2019 Stormont Vail Health Partners with Omnicell to Enhance Medication Management Str...
Mar 06, 2019 Rebranding Focuses ALG Mission - Combining Our Best to Bring You Our Best
Mar 04, 2019 RXinsider Celebrates 20 Years, 1999 - 2019
Feb 18, 2019 QS/1® Offers Compliance Packaging Label Solution
Feb 15, 2019 QS/1 Partnership Offers Compliant Patient Communications
Feb 14, 2019 RXinsider is Proud to Welcome our Newest Partners!
Feb 12, 2019 Albertsons Companies Pharmacies Adopt TemperPack's ClimaCell™ Packaging
Feb 07, 2019 Fagron Launches New Brand Identity and Purpose
Feb 07, 2019 Medicine-On-Time has come together with Clinical Support Services, a leader in M...
Feb 04, 2019 Letco Med and Ananda Professional Partner to Bring CBD and Education to Compound...
Jan 30, 2019 Texas Children’s Hospital Expands Partnership with Omnicell
Jan 16, 2019 Helmer Scientific Launches the First Professional Medical-grade Refrigerators
Jan 15, 2019 The Compliance Team™ celebrates 25 years of accreditation transformation
Jan 11, 2019 CORE Higher Education Group partners with Pharmacists Mutual
Jan 10, 2019 SCA Pharma Awarded National Outsourced I.V. Admixture Services Agreement with Pr...
Jan 08, 2019 Tutela Welcomes the Center for Organ Recovery and Education
Dec 13, 2018 PharmaLink Launches Updated Website
Dec 11, 2018 Jorgenson Issues Annual List of Major Challenges Facing Hospital and Health Syst...
Nov 29, 2018 BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversi...
Nov 13, 2018 Akro-Mils 2019 Catalog
Nov 13, 2018 New Data Shows Many Health System Pharmacies Considering Consolidated Distributi...
Oct 17, 2018 Retail Management Solutions Celebrates 20 Years of Pharmacy POS Innovation

RXinsider Product Overview Videos